FDA Approves Orserdu for ER+ MBC (oral SERD)
moderators
Posts: 9,938
FDA Approves Orserdu for Metastatic, Estrogen Receptor-Positive Breast Cancer
Jan 27, 2023
The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation. Read more....
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your profile.